Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Ventyx Biosciences has been one of 2025’s biggest small-cap biotech movers. The Nasdaq-listed stock jumped sharply on Oct. 22 after hours, when the company announced the positive Phase 2 data. On Oct. 22 regular trading, VTYX ended at $3.86 marketbeat.com, but in electronic after-hours trading it skyrocketed roughly 85–90%, touching the low $7’s marketbeat.com benzinga.com. By early Oct. 23 the stock was quoting around $3.86, reflecting profit-taking after the spike. Over the past six months, the stock had already climbed over 230%, driven by pipeline optimism benzinga.com. Analysts note that before the news, shares were near the bottom of their 52-week range and have now hit multi‑year highs.